AQST
Price
$2.27
Change
-$0.12 (-5.02%)
Updated
May 21 closing price
Capitalization
383.26M
82 days until earnings call
DERM
Price
$6.78
Change
-$0.10 (-1.45%)
Updated
May 21 closing price
Capitalization
73.35M
82 days until earnings call
Interact to see
Advertisement

AQST vs DERM

Header iconAQST vs DERM Comparison
Open Charts AQST vs DERMBanner chart's image
Aquestive Therapeutics
Price$2.27
Change-$0.12 (-5.02%)
Volume$1.29M
Capitalization383.26M
Journey Medical
Price$6.78
Change-$0.10 (-1.45%)
Volume$94.76K
Capitalization73.35M
AQST vs DERM Comparison Chart
Loading...
AQST
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DERM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AQST vs. DERM commentary
May 22, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AQST is a Hold and DERM is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
May 22, 2025
Stock price -- (AQST: $2.27 vs. DERM: $6.78)
Brand notoriety: AQST: Not notable vs. DERM: Notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: AQST: 86% vs. DERM: 97%
Market capitalization -- AQST: $383.26M vs. DERM: $73.35M
AQST [@Pharmaceuticals: Other] is valued at $383.26M. DERM’s [@Pharmaceuticals: Other] market capitalization is $73.35M. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $77.48B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $3.7B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AQST’s FA Score shows that 0 FA rating(s) are green whileDERM’s FA Score has 0 green FA rating(s).

  • AQST’s FA Score: 0 green, 5 red.
  • DERM’s FA Score: 0 green, 5 red.
According to our system of comparison, DERM is a better buy in the long-term than AQST.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AQST’s TA Score shows that 4 TA indicator(s) are bullish while DERM’s TA Score has 5 bullish TA indicator(s).

  • AQST’s TA Score: 4 bullish, 5 bearish.
  • DERM’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, DERM is a better buy in the short-term than AQST.

Price Growth

AQST (@Pharmaceuticals: Other) experienced а +2.25% price change this week, while DERM (@Pharmaceuticals: Other) price change was +13.57% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +0.61%. For the same industry, the average monthly price growth was +11.90%, and the average quarterly price growth was +28.86%.

Reported Earning Dates

AQST is expected to report earnings on Aug 12, 2025.

DERM is expected to report earnings on Aug 12, 2025.

Industries' Descriptions

@Pharmaceuticals: Other (+0.61% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AQST($383M) has a higher market cap than DERM($73.4M). DERM YTD gains are higher at: 73.402 vs. AQST (-36.236). AQST has higher annual earnings (EBITDA): 1.18M vs. DERM (-5.69M). DERM (24.7M) and AQST (23.9M) have equal amount of cash in the bank . DERM has less debt than AQST: DERM (131K) vs AQST (33.3M). DERM has higher revenues than AQST: DERM (79.9M) vs AQST (50.6M).
AQSTDERMAQST / DERM
Capitalization383M73.4M522%
EBITDA1.18M-5.69M-21%
Gain YTD-36.23673.402-49%
P/E RatioN/AN/A-
Revenue50.6M79.9M63%
Total Cash23.9M24.7M97%
Total Debt33.3M131K25,420%
FUNDAMENTALS RATINGS
AQST vs DERM: Fundamental Ratings
AQST
DERM
OUTLOOK RATING
1..100
1467
VALUATION
overvalued / fair valued / undervalued
1..100
34
Fair valued
67
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
8537
P/E GROWTH RATING
1..100
10040
SEASONALITY SCORE
1..100
n/a35

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

AQST's Valuation (34) in the Pharmaceuticals Major industry is somewhat better than the same rating for DERM (67) in the Biotechnology industry. This means that AQST’s stock grew somewhat faster than DERM’s over the last 12 months.

AQST's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as DERM (100) in the Biotechnology industry. This means that AQST’s stock grew similarly to DERM’s over the last 12 months.

AQST's SMR Rating (100) in the Pharmaceuticals Major industry is in the same range as DERM (100) in the Biotechnology industry. This means that AQST’s stock grew similarly to DERM’s over the last 12 months.

DERM's Price Growth Rating (37) in the Biotechnology industry is somewhat better than the same rating for AQST (85) in the Pharmaceuticals Major industry. This means that DERM’s stock grew somewhat faster than AQST’s over the last 12 months.

DERM's P/E Growth Rating (40) in the Biotechnology industry is somewhat better than the same rating for AQST (100) in the Pharmaceuticals Major industry. This means that DERM’s stock grew somewhat faster than AQST’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AQSTDERM
RSI
ODDS (%)
Bullish Trend 1 day ago
89%
Bearish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
87%
Bullish Trend 1 day ago
90%
Momentum
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 1 day ago
90%
MACD
ODDS (%)
Bearish Trend 1 day ago
85%
Bearish Trend 1 day ago
78%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
90%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
85%
Bullish Trend 1 day ago
87%
Advances
ODDS (%)
Bullish Trend 10 days ago
84%
Bullish Trend 28 days ago
88%
Declines
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 3 days ago
88%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
86%
Bullish Trend 1 day ago
90%
Aroon
ODDS (%)
N/A
Bullish Trend 1 day ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
AQST
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DERM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
JEMCX31.51N/A
N/A
JPMorgan Emerging Markets Equity C
MISEX34.94N/A
N/A
Midas Special Opportunities
HRMDX13.51N/A
N/A
Heartland Mid Cap Value Investor
TNRAX18.39N/A
N/A
1290 Avantis U.S. Large Cap Growth A
JAAGX83.29-1.72
-2.02%
Janus Henderson VIT Enterprise Instl

AQST and

Correlation & Price change

A.I.dvisor indicates that over the last year, AQST has been loosely correlated with OGI. These tickers have moved in lockstep 33% of the time. This A.I.-generated data suggests there is some statistical probability that if AQST jumps, then OGI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AQST
1D Price
Change %
AQST100%
-5.02%
OGI - AQST
33%
Loosely correlated
-0.74%
ETON - AQST
33%
Poorly correlated
+3.27%
SCYX - AQST
32%
Poorly correlated
-3.58%
DERM - AQST
31%
Poorly correlated
-1.45%
TLRY - AQST
31%
Poorly correlated
-4.42%
More

DERM and

Correlation & Price change

A.I.dvisor tells us that DERM and AQST have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that DERM and AQST's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DERM
1D Price
Change %
DERM100%
-1.45%
AQST - DERM
31%
Poorly correlated
-5.02%
CHRS - DERM
27%
Poorly correlated
-5.29%
VXRT - DERM
24%
Poorly correlated
-9.98%
CRDL - DERM
23%
Poorly correlated
-5.36%
DRMA - DERM
22%
Poorly correlated
-4.67%
More